Literature DB >> 12771415

The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation.

M Esteban1, M A García1, E Domingo-Gil1, J Arroyo2, C Nombela2, C Rivas2.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) uses several strategies to counteract the interferon (IFN) system. In this study, the relationship of the protein LANA2 from KSHV to the IFN-activated protein kinase (PKR) and 2-5A system was analysed. It was found that LANA2 could not abrogate apoptosis or RNA degradation mediated by the 2-5A system. However, expression of LANA2 inhibited apoptosis triggered by PKR. LANA2 also counteracted the PKR-mediated inhibition of protein synthesis and partially blocked PKR-induced phosphorylation of eIF-2alpha. Analysis of PKR-induced activation of caspases 3 and 9 revealed that LANA2 abrogated activation of caspase 3 but not of caspase 9. These findings show that LANA2 is able to interfere with downstream events triggered by PKR. Hence, LANA2 should be considered as a KSHV defence protein against IFN.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771415     DOI: 10.1099/vir.0.19014-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  26 in total

1.  Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2.

Authors:  C Muñoz-Fontela; L Marcos-Villar; F Hernandez; P Gallego; E Rodriguez; J Arroyo; S-J Gao; J Avila; C Rivas
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

Review 2.  Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication.

Authors:  Emily Cousins; John Nicholas
Journal:  Recent Results Cancer Res       Date:  2014

Review 3.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

4.  Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression.

Authors:  Katharina Schmidt; Effi Wies; Frank Neipel
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

Review 5.  Viruses associated with human cancer.

Authors:  Margaret E McLaughlin-Drubin; Karl Munger
Journal:  Biochim Biophys Acta       Date:  2007-12-23

6.  Angiogenesis, Kaposi's Sarcoma and Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Tao Kang; Feng-Chun Ye; Shou-Jiang Gao; Lin-Ding Wang
Journal:  Virol Sin       Date:  2008-12-01       Impact factor: 4.327

7.  The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5.

Authors:  Effi Wies; Alexander S Hahn; Katharina Schmidt; Cornelia Viebahn; Nadine Rohland; Anja Lux; Tim Schellhorn; Angela Holzer; Jae U Jung; Frank Neipel
Journal:  J Biol Chem       Date:  2009-01-07       Impact factor: 5.157

8.  The viral interferon regulatory factors of kaposi's sarcoma-associated herpesvirus differ in their inhibition of interferon activation mediated by toll-like receptor 3.

Authors:  Sarah R Jacobs; Sean M Gregory; John A West; Amy C Wollish; Christopher L Bennett; David J Blackbourn; Mark T Heise; Blossom Damania
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

9.  Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3.

Authors:  Chul Hyun Joo; Young C Shin; Michaela Gack; Liguo Wu; David Levy; Jae U Jung
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

10.  Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene.

Authors:  Laura Marcos-Villar; Fernando Lopitz-Otsoa; Pedro Gallego; Cesar Muñoz-Fontela; José González-Santamaría; Michela Campagna; Gao Shou-Jiang; Manuel S Rodriguez; Carmen Rivas
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.